drugset / Trial / NCT00797472
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease
Phase 2
Unknown
120 enrolled
American Scitech International
Bristol-Myers Squibb · collabEli Lilly and Company · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine. R-mabHD will be given once a week for eight weeks in a row. The ABVD combination will be given once every other week for 12 treatments. The hypothesis is that intervention with R-mabHD will lead to a quicker remission of Hodgkin's disease than the intervention with a combination of ABVD.
Timeline
- Start
- 2011-07
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bleomycin | Unknown | — | Intravenous |
| Comparator | Dacarbazine | Small molecule | — | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | — | Intravenous |
| Comparator | R-mabHD | Unknown | 375 mg/m2 | Intravenous |
| Comparator | Vinblastine | Small molecule | — | Intravenous |